CHARLOT BIOSCIENCES INC

Irvine, CA · Medtech · Private

cellPhoresis®, a mobile microfluidics platform using electric field-induced cell motility differentiation to rapidly identify bacterial strains and their susceptibility to treatments

cbio.io →
Grants
$299K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
$750K
1 award · Defense
#347 of 4531 in medtech
Patents
2
1 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Defense · Phase I · Rapid Detection of Bacteriophage Susceptibility in Antibiotic-Resistant Pathogens using cellPhoresis®$249,534
Federal grant· 2 of 2 same dayDepartment of Defense · Phase I · Rapid Pathogen Threat Detection in Aerial and Field Environments$49,869
Federal contractDepartment of Defense · Rapid Pathogen Threat Detection In Aerial And Field Environments$749,574
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
344SIMPHOTEK, INC.$755K$1.1M
345NanoEngineering Corporation$753K$1.4M
346RESOURCEPATH LLC$750K—
347CHARLOT BIOSCIENCES INC$750K—
348VAXESS TECHNOLOGIES INC$749K—
349LifeCanvas Technologies Inc.$738K—
350PACIFIC OPTICA, INC.$734K—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 2

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.